Significant growth trajectory of the Breast Cancer Application segment, which is expected to reach US$374.1 Million by 2030 ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of waveLINE-010, a pivotal ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the combination will be assessed against rituximab with cyclophos ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

A study reveals a novel adhesive patch prototype using AgNP-Cx+ for enhanced anti-tumor activity against melanoma, showcasing ...

A doctor at a local cancer institute hopes to do more clinical studies to see if lab findings apply to actual patients. Read ...

Monopar Therapeutics Inc.’s MNPR share price has surged by 10.22%, which has investors questioning if this is right time to sell.

Melanoma is a fast-progressing skin cancer characterized by a high mortality rate after metastasis. Local chemotherapy could ...

A new study published in Drug Design, Development and Therapy suggests that cannabidiol (CBD) may help protect the heart from ...

Doxorubicin is under clinical development by Shanghai Affinity Biopharmaceutical and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% ...